Current Issue
Volume: 38
Number: 4
Index: December 2010
Clinical Focus:Respiratory Care
Editorial Calendar
December 2010
Clinical Focus: Respiratory Medicine
  • Asthma and the athlete
    • Vocal cord dysfunction
    • Exercise-induced asthma
    • Exercise-induced bronchospasm
  • COPD
    • Obesity and COPD
    • Relationship between COPD and nutrition intake
  • Treatment options for steroid-induced osteoporosis in men
  • Treatments for asthma
    • Bronchodilators, anticholinergics
    • Corticosteroids
    • Metered-dose vs other types of inhalers
  • Respiratory infections in winter sports athletes
  • Asthma in elite athletes
  • Pulmonary rehabilitation and physical activity
  • Fitness and long-term oxygen therapy/lung transplantation
  • Airflow function and the metabolic syndrome
View More
Submission deadline: November 05
Fast-Track deadline: November 15
Fast-Track peer review is available for those papers requiring immediate review (for an additional fee). Complete peer review is finalized in 1-2 weeks and comments are provided to the author within 72 hours of their receipt by the editorial office. Authors are asked to submit a revised manuscript within 10-12 days. Accepted manuscripts are processed within 2-3 weeks, published online within 3 business days of final author approval, and in print in the next available issue.
Submit your FAST-TRACK manuscript online today. It's fast, it's easy! Just follow the detailed instructions, fill in all the required fields, and upload your manuscript.
Get started NOW!
[email protected]

[email protected]

[email protected]

[email protected]

Document Delivery Services

[email protected]

[email protected] [email protected]

[email protected]

Managing Director:
John Elduff
Phone: 610-889-3732
Fax: 1-866-297-3168
[email protected]

General Information
Phone: 610-889-3730
Fax: 1-866-297-3168
1235 Westlakes Drive
Suite 320
Berwyn, PA 19312
doi: 10.3810/psm.2021.12.3
The Physician and Sportsmedicine: Volume 36: No.1
JUPITER Study Shows Crestor® Significantly Lowers Major Cardiovascular (CV) Events
The JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial, a long-term, randomized, double-blind, placebo-controlled, large scale study of 17 802 patients, confirmed that AstraZeneca's Crestor® (rosuvastatin calcium) dramatically reduces LDL-C cholesterol levels. Crestor® 20 mg showed a 44% decrease of major CV events (the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) compared with placebo (P < 0.001) among men and women with elevated high sensitivity C-reactive protein (hsCRP) but low to normal cholesterol levels. The results of the trial were presented at the American Heart Association's Scientific Sessions. The investigators found that rosuvastatin 20 mg was well tolerated in nearly 9000 patients during the course of the study, finding no difference between treatment groups for major adverse events, including cancer or myopathy, and found a small increase in physician reported diabetes consistent with data from previous placebo-controlled statin trials.


Back to the table of contents for the December 2021 issue